Alendronate Sodium Tablets, manufactured by Teva Pharmaceuticals (North Wales, PA), is indicated for the treatment and prevention of osteoporosis in postmenopausal women; treatment to increase bone mass in men with osteoporosis; treatment of glucococorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density; and treatment of Paget's disease of bone in men and women. The product is AB-rated and bioequivalent to Merck and Co's Fosamax Tablets.
MiraLAX, manufactured by Schering-Plough HealthCare Products Inc (Kenilworth, NJ), is an OTC laxative that works with an individual's body to relieve constipation. MiraLAX restores the body's natural rhythm by using the body's own water to gently increase the frequency of bowel movements and to soften stools. Taken once daily, each dose contains 16 g of polyethylene glycol 3350 powder, which is dissolved in 4 to 8 oz of liquid for ease of consumption.
Immediate-release Oxycodone HCl Tablets, manufactured by ETHEX Corp (St. Louis, MO), is a now available in 10 and 20 mg tablets. The new 10- and 20-mg strengths are designed to bridge the gap between existing oxycodone HCl strengths, providing prescribers and patients with greater dosing flexibility. These tablets are indicated for the relief of moderate-to-severe pain where the use of an opioid analgesic is appropriate. The product is available in 5,10,15, 20, and 30 mg.
Although the annual HIV diagnosis rate between 2010 and 2014 decreased for black individuals by 16.2%, blacks remain disproportionately affected by HIV/AIDS.
Clinical features with downloadable PDFs